Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

2.13p
   
  • Change Today:
    -0.055p
  • 52 Week High: 3.42p
  • 52 Week Low: 0.85p
  • Currency: UK Pounds
  • Shares Issued: 416.44m
  • Volume: 2,365,381
  • Market Cap: £8.85m
  • RiskGrade: 328

ImmuPharma's US partner receives FDA response on Lupuzor

By Josh White

Date: Wednesday 14 Sep 2022

LONDON (ShareCast) - (Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Wednesday that its US partner for 'Lupuzor', Avion Pharmaceuticals, has received a written response from the Food and Drug Administration (FDA).
The AIM-traded firm said the FDA's response was "detailed", and included "significant guidance" on the next steps for the clinical programme.

It said that included advice on the dosing regime.

"In addition, the FDA also provided further significant guidance on the study protocol that can be amended to improve the regulatory outcome," the board said in its statement.

"The company is currently reviewing the written response with Avion and will make a further notification in due course."

At 1342 BST, shares in ImmuPharma were down 29.31% at 4.68p.

Reporting by Josh White at Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Immupharma Market Data

Currency UK Pounds
Share Price 2.13p
Change Today -0.055p
% Change -2.52 %
52 Week High 3.42p
52 Week Low 0.85p
Volume 2,365,381
Shares Issued 416.44m
Market Cap £8.85m
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
64.42% below the market average64.42% below the market average64.42% below the market average64.42% below the market average64.42% below the market average
18.52% below the sector average18.52% below the sector average18.52% below the sector average18.52% below the sector average18.52% below the sector average
Price Trend
4.00% above the market average4.00% above the market average4.00% above the market average4.00% above the market average4.00% above the market average
47.37% above the sector average47.37% above the sector average47.37% above the sector average47.37% above the sector average47.37% above the sector average
Income Not Available
Growth Not Available

Immupharma Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:17 14,000 @ 2.08p
16:13 22,386 @ 2.20p
16:13 9,454 @ 2.20p
16:13 10,000 @ 2.15p
16:12 15,000 @ 2.15p

Immupharma Key Personnel

CEO Timothy Paul McCarthy

Top of Page